London · Delayed Price · Currency is GBP · Price in USD FibroGen Statistics
Total Valuation
FibroGen has a market cap or net worth of GBP 21.02 million. The enterprise value is 96.20 million.
| Market Cap | 21.02M |
| Enterprise Value | 96.20M |
Important Dates
The next estimated earnings date is Monday, August 4, 2025.
| Earnings Date | Aug 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 4.04M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +2.20% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 3.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.88 |
| PB Ratio | -0.16 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -12.42 |
| EV / Sales | 18.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.63 |
Financial Position
The company has a current ratio of 2.02
| Current Ratio | 2.02 |
| Quick Ratio | 0.46 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.20 |
| Interest Coverage | -11.48 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -22.73% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -105.17% |
| Revenue Per Employee | 24,066 |
| Profits Per Employee | -34,424 |
| Employee Count | 225 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 4.12 |
Taxes
| Income Tax | -212,073 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.11% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -47.11% |
| 50-Day Moving Average | 7.73 |
| 200-Day Moving Average | 9.63 |
| Relative Strength Index (RSI) | 41.45 |
| Average Volume (20 Days) | 628 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.49 |
Income Statement
In the last 12 months, FibroGen had revenue of GBP 5.41 million and -7.75 million in losses. Loss per share was -1.93.
| Revenue | 5.41M |
| Gross Profit | -43.23M |
| Operating Income | -74.75M |
| Pretax Income | -93.72M |
| Net Income | -7.75M |
| EBITDA | -73.05M |
| EBIT | -74.75M |
| Loss Per Share | -1.93 |
Balance Sheet
The company has 26.01 million in cash and 70.60 million in debt, giving a net cash position of -44.59 million.
| Cash & Cash Equivalents | 26.01M |
| Total Debt | 70.60M |
| Net Cash | -44.59M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -135.39M |
| Book Value Per Share | -41.54 |
| Working Capital | 58.16M |
Cash Flow
In the last 12 months, operating cash flow was -58.82 million and capital expenditures -195,819, giving a free cash flow of -59.01 million.
| Operating Cash Flow | -58.82M |
| Capital Expenditures | -195,819 |
| Free Cash Flow | -59.01M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,380.42% |
| Pretax Margin | -1,730.87% |
| Profit Margin | -143.04% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FibroGen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.20% |
| Shareholder Yield | n/a |
| Earnings Yield | -36.84% |
| FCF Yield | -280.70% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 17, 2025. It was a reverse split with a ratio of 0.04.
| Last Split Date | Jun 17, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.04 |
Scores
FibroGen has an Altman Z-Score of -17.19 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -17.19 |
| Piotroski F-Score | 1 |